The AlzeCure Foundation is focused on the development of novel diagnostics and therapeutics for PD.
AlzeCure Pharma has raised $3.3M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in April 2026.
AlzeCure Pharma's investors include European Innovation Council, Linbo Invest, Niklas Estensson, Alexander Schoeneck, Jan Poulsen.
AlzeCure Pharma is headquartered in Stockholm, Sweden.
The AlzeCure Foundation is focused on the development of novel diagnostics and therapeutics for PD.
AlzeCure Pharma is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AlzeCure Pharma — Funding & Investors." VCBacked, April 24, 2026, https://www.vcbacked.co/company/alzecure-pharma. Accessed November 7, 2026.
VCBacked. (2026). AlzeCure Pharma — Funding & Investors. Retrieved November 7, 2026, from https://www.vcbacked.co/company/alzecure-pharma
{{cite web |title=AlzeCure Pharma — Funding & Investors |url=https://www.vcbacked.co/company/alzecure-pharma |website=VCBacked |access-date=November 7, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at AlzeCure Pharma? Request a listing update